Navigation Links
Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/6/2012

included a $15.0 million milestone payment from Lilly in connection with the launch of BYDUREON in the European Union in July, compared to $17.7 million for the same period in 2010, which included $10 million in milestone revenue earned upon the launch of BYETTA in Japan.

Selling, general and administrative expenses decreased to $271.2 million for the twelve months ended December 31, 2011 from $276.9 million for the same period in 2010. The decrease primarily reflects reduced business infrastructure spending resulting from continued efforts to drive efficiencies in the business, offset by higher expenses due to BYDUREON pre-launch activities.

Research and development expenses decreased to $161.2 million for the twelve months ended December 31, 2011 from $183.1 million for the same period in 2010. The decrease reflects the favorable disposition of certain cost-sharing disputes with Lilly, partially offset by increased spending on our metreleptin lipodystrophy development program.

Collaborative profit sharing was $222.5 million for the twelve months ended December 31, 2011, compared to $257.1 million for the same period in 2010. The decrease is due to the termination of the Lilly collaboration.

Interest and other expense, net, increased to $51.9 million for the twelve months ended December 31, 2011 from $25.6 million for the same period in 2010. The increase primarily reflects increased interest expense on the Company's debt, resulting from the promissory note related to the RSO entered into in connection with the Settlement Agreement, and a loss on a fair value adjustment to a derivative asset.

Non-GAAP operating income was $25.7 million for the twelve months ended December 31, 2011 compared to a non-GAAP operating loss of $4.4 million for the same period in 2010. GAAP net loss for the twelve months ended December 31, 2011 was $543.4 million, or $3.73 per share, compared to GAAP net loss of $152.3 million, or $1.06 per share for the
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, Inc. ... announced it has completed the sale to Galderma of ... owned or held by Valeant for $1.4 billion in ... S.A, which recently completed its acquisition of Galderma. ... of our products to a company that is firmly ...
(Date:7/10/2014)... 2014  Decision Resources Group finds that while ... specialists are willing to prescribe Durata,s Dalvance (dalbavancin) ... as OPAT, approximately two-thirds of the respondents reported ... hospital inpatients. However, our findings indicate that nearly ... on OPAT following hospital discharge, and most are ...
(Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation (NYSE: ... directors has approved a quarterly dividend of $0.275 (27.5 cents) ... payable on August 1, 2014, to holders of record on ... CVS Caremark is dedicated to helping people on their ... in the United States . Through the ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... Omthera Pharmaceuticals, Inc., a privately-held emerging specialty ... and Chief Executive Officer, will present at the ... InterContinental Boston, in Boston, Massachusetts, on Wednesday, June ... About Omthera Pharmaceuticals, Inc.Founded in 2008, Omthera ...
... Alere Inc. (NYSE: ALR ) (the "Company") ... each of its consent solicitations commenced on May 31, ... the "Proposed Modifications") governing its 9.0% Senior Subordinated Notes ... due 2018 (the "8.625% Notes") and 7.875% Senior Notes ...
Cached Medicine Technology:
(Date:7/11/2014)... Europe Well Intervention Market report defines and segments the well ... The well intervention services market in Europe is estimated to ... by 2018, at a CAGR of 7% from 2013 to ... Intervention Market report, to get an idea of the in-depth ... in the Europe well intervention market, and is supported by ...
(Date:7/11/2014)... News) -- In people with sex addiction, pornography affects ... seen in drug addicts as they consume drugs, a ... brain activity between patients who have compulsive sexual behavior ... addicts," study author Dr. Valerie Voon, of the University ... release. Voon,s research involved 19 men with sex ...
(Date:7/11/2014)... The report “Probiotics Market by Products (Functional ... (Regular, Therapeutic, Preventive Health Care) & Ingredients (Lactobacilli, ... 2019 ” defines and segments the global probiotics ... market value of probiotic products and ingredients. The ... for the global market with an analysis of ...
(Date:7/11/2014)... 2014 Biostimulants are widely applied in ... and ornamentals. These also help turf and ornamentals in ... roots. Turf, ornamentals, and flowers appear healthy and strong ... has increased from the last few years. The most ... is Europe, with around 40% share in 2013, and ...
(Date:7/11/2014)... 2014) Obese and overweight firefighters are not ... providers, according to new research from The University ... , National guidelines state that health care professionals ... maintaining a healthy weight. Firefighters have high rates ... cause of line-of-duty deaths in firefighters. This study ...
Breaking Medicine News(10 mins):Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
... innovative approach to treating neonatal feeding problems at Nationwide ... feed orally to be discharged earlier and without feeding ... According to American Academy of Pediatrics guidelines, in ... hospital, they must establish safe oral feeding methods. The ...
... This press release is available in German . ... the biggest risk factors for the development of gastric cancer, the ... biologists from the University of Zurich have now identified a mechanism ... gastric mucosa and sets them up for malignant transformation. Gastric ...
... -- Doctors have been prescribing codeine for postpartum pain management ... to breastfeed while taking the opioid. But the death ... many health care providers questioning the safety of the drug ... risks, some doctors have begun the practice of prescribing oxycodone ...
... HealthDay Reporter , MONDAY, Sept. 5 (HealthDay News) -- Living ... as much as 80 percent, researchers from the U.S. National ... diet, exercise, smoking and drinking have an impact on whether ... each individual factor affects the risk had been unclear. ...
... 6 (HealthDay News) -- There,s no link between menopause ... a study that challenges a long-held medical belief that ... menopause. Aging alone, not the hormonal impact of ... women, according to the Johns Hopkins researchers. The ...
... Sept. 6 (HealthDay News) -- Some children, especially those ... the hospital, a new study finds. Acetaminophen, albuterol ... hospitalized children, the researchers said. They also found an ... of drugs given to children. On the first ...
Cached Medicine News:Health News:Neonatal and infant feeding disorders program saves infants from lifetime of feeding tubes 2Health News:Stomach bacterium damages human DNA 2Health News:Mother's postpartum oxycodone use: No safer for breastfed infants than codeine 2Health News:Healthy Living Can Cut Chances of Developing Diabetes 2Health News:Aging, Not Menopause, Raises Women's Heart Risks, Study Finds 2Health News:Hospitalized Kids May Receive Up to 35 Meds a Week 2
... Beta 200 ophthalmoscope, ... glare-free direct ophthalmoscope. Heine's ... patent #4,963,014) along with ... construction, make the Beta ...
... optics. The separation of illumination and observation ... system avoids corneal and iris reflex (Gullstrand-principle). ... the whole of the illuminated section of ... Conventional ophthalmoscopes often let you see only ...
... Beta 200S is the first ... combination of patented aspherical optics ... range of corrective lenses from ... single diopter steps. A perfectly-focused ...
With the unique automatic focus system, Autofoc 2 remains the instrument of choice for direct ophthalmoscopy. Includes XHL halogen bulb....
Medicine Products: